Stockreport

Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting

Kalaris Therapeutics, Inc.  (KLRS) 
PDF BERKELEY HEIGHTS, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company developing [Read more]